AMG 133, a new experimental drug combining two appetite-control mechanisms, produced sustained weight loss in obese mice and monkeys through once-weekly injections, according to research published in the Journal of Medicinal Chemistry. Gram Research analysis shows this antibody-drug conjugate blocks one hunger hormone while boosting another, potentially allowing monthly dosing in humans when approved. The drug is currently in phase III clinical trials.
Scientists have created a new experimental drug called AMG 133 that works like a one-two punch against obesity. Instead of using a single approach, this drug combines two different strategies: it blocks one hunger hormone while boosting another that helps control appetite and blood sugar. In animal studies, mice and monkeys given this drug once a week lost significant weight and showed better metabolic health. The drug is now being tested in humans through phase III clinical trials, with the goal of eventually requiring just one injection per month. This represents an exciting advance in obesity treatment using what researchers call ‘multispecific therapeutics’—drugs designed to target multiple systems at once.
Key Statistics
A 2026 research article in the Journal of Medicinal Chemistry reported that AMG 133, an antibody-drug conjugate combining GIPR antagonism with GLP-1 receptor agonism, produced sustained body weight loss in diet-induced obese mice and obese monkeys with once-weekly administration.
According to preclinical research published in 2026, AMG 133 improved multiple metabolic parameters beyond weight loss in animal models, with a drug profile suggesting potential for monthly dosing in humans compared to weekly injections required by current GLP-1 medications.
A 2026 study in the Journal of Medicinal Chemistry demonstrated that conjugating GLP-1 peptides to anti-GIPR antibodies yielded markedly prolonged systemic exposure of the structurally intact GLP-1 peptide, enabling less frequent dosing schedules in obesity treatment.
The Quick Take
- What they studied: Whether combining two different appetite-control mechanisms in a single drug could be more effective for weight loss than using just one approach.
- Who participated: The research used laboratory mice that were made obese through diet, and obese monkeys. This was preclinical research, meaning it was done in animals before human testing.
- Key finding: Once-weekly injections of AMG 133 produced sustained weight loss and improved metabolic health markers in both obese mice and obese monkeys, with the potential for monthly dosing in humans.
- What it means for you: If approved, this drug could offer a more convenient treatment option (monthly injections instead of weekly) that works through two complementary mechanisms. However, this is still in clinical trials, so safety and effectiveness in humans must be confirmed before it becomes available.
The Research Details
Researchers created a new type of drug by combining two components: an antibody (a protein that fights disease) designed to block GIPR (a hunger hormone receptor) and a GLP-1 peptide (a synthetic version of a natural appetite-suppressing hormone). They attached the GLP-1 peptide directly to the antibody, creating what’s called an ‘antibody-drug conjugate.’ This approach allows both components to stay in the body much longer than if used separately.
The team tested this combined drug in two animal models: first in mice that had been fed a high-fat diet to make them obese, and then in obese monkeys. They gave the animals injections once per week and measured changes in body weight and metabolic markers (like blood sugar and insulin levels).
This research approach is called ‘multispecific therapeutics,’ which means using one drug to target multiple biological pathways simultaneously. The researchers optimized many versions of this drug combination before settling on AMG 133, which showed the best results and the potential for less frequent dosing in humans.
Traditional obesity drugs typically work through a single mechanism—they either reduce appetite or increase energy burning. By combining two complementary approaches in one molecule, researchers hoped to achieve better weight loss results with potentially fewer side effects. The antibody component also allows the drug to stay in the bloodstream much longer, which could mean less frequent injections for patients.
This research was published in the Journal of Medicinal Chemistry, a respected peer-reviewed publication. The work progressed from laboratory design through animal testing to human clinical trials (phase III), which demonstrates scientific rigor. However, because this is preclinical research (animal studies), results may not directly translate to humans. The fact that the drug showed consistent results in two different animal species (mice and monkeys) strengthens confidence in the findings.
What the Results Show
AMG 133 produced sustained body weight loss in both obese mice and obese monkeys when given as once-weekly injections. The weight loss was maintained over the study period, suggesting the drug’s effects don’t wear off quickly. Beyond weight loss, the drug improved multiple metabolic parameters—measurements of how well the body processes food and maintains blood sugar levels.
The dual-action mechanism appears to be key to the drug’s effectiveness. By blocking GIPR (which normally stimulates hunger and reduces energy burning), the drug reduces appetite. Simultaneously, by activating GLP-1 receptors (which naturally suppress appetite and improve insulin function), the drug provides additional appetite control and better blood sugar management. This combination appears to work synergistically—meaning the two actions together are more powerful than either one alone.
The antibody component of the drug allowed the GLP-1 peptide to remain structurally intact and active in the bloodstream for extended periods. This extended exposure is important because it means the drug can work longer between doses. The research team optimized the drug design to achieve these results, eventually creating AMG 133, which showed a profile suggesting monthly dosing might be possible in humans—a significant convenience advantage over weekly injections.
The research demonstrated that the antibody-peptide conjugate approach successfully extended the time the GLP-1 component remains active in the body compared to GLP-1 peptides used alone. This extended systemic exposure is crucial for reducing dosing frequency. The consistent results across two different animal species (mice and monkeys) suggest the drug’s mechanism is robust and likely to translate to human biology. Metabolic improvements beyond weight loss—including better blood sugar control and insulin function—suggest the drug may provide benefits beyond appetite suppression.
According to Gram Research analysis, this work builds on existing GLP-1 receptor agonist drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro), which have shown significant weight loss benefits. However, AMG 133 represents a novel approach by combining GLP-1 activation with GIPR antagonism in a single molecule. Previous research suggested that blocking GIPR while activating GLP-1 could produce superior weight loss, and this study provides the first detailed characterization of such a combined antibody-drug conjugate. The monthly dosing potential represents an advancement over current GLP-1 drugs, which typically require weekly or twice-weekly injections.
This research was conducted entirely in animals (mice and monkeys), not humans. Animal studies don’t always predict human results—what works in mice may not work the same way in people. The abstract doesn’t provide specific numbers for how much weight was lost or how much metabolic markers improved, making it difficult to compare the magnitude of effects to existing obesity treatments. The study design and duration aren’t fully detailed in the available information. Because AMG 133 is still in phase III clinical trials, its safety profile and real-world effectiveness in humans remain to be determined. Long-term effects beyond the study period are unknown.
The Bottom Line
This research is promising but preliminary. AMG 133 should not be considered an available treatment yet—it’s still in clinical trials. If you’re interested in obesity treatment now, discuss FDA-approved GLP-1 receptor agonists (like semaglutide or tirzepatide) with your healthcare provider. If you have obesity and are considering any weight-loss medication, work with a doctor to determine what’s appropriate for your individual health situation. Monitor clinical trial announcements if you’re interested in potentially participating in AMG 133 studies. Confidence level: Moderate for animal efficacy; Low for human application until phase III results are published.
People with obesity or overweight conditions who are interested in medication options should follow this research. Healthcare providers treating obesity should monitor AMG 133’s development. People who have not responded well to current GLP-1 drugs might particularly benefit if AMG 133 proves more effective. People with diabetes or metabolic syndrome should pay attention, as the drug appears to improve blood sugar control. This research is less immediately relevant for people at healthy weight or those preferring non-medication approaches to weight management.
AMG 133 is currently in phase III clinical trials, which typically take 1-3 years to complete. If successful, the drug would need FDA approval before becoming available to patients, which could take additional months to years. Realistic timeline for potential availability: 2-4 years at minimum, assuming positive trial results. Once available, weight loss typically becomes noticeable within 4-8 weeks of starting GLP-1-based medications, with maximum effects usually seen after 3-6 months of consistent use.
Frequently Asked Questions
How does AMG 133 work differently from current weight loss drugs like Ozempic or Wegovy?
AMG 133 combines two mechanisms in one drug: it blocks GIPR (a hunger-stimulating hormone) while activating GLP-1 (an appetite-suppressing hormone). Current drugs typically use only GLP-1 activation. The dual approach may produce greater weight loss, and the antibody component allows monthly dosing instead of weekly injections.
When will AMG 133 be available to patients?
AMG 133 is currently in phase III clinical trials, the final stage before potential FDA approval. Realistic timeline for availability is 2-4 years minimum, assuming positive trial results. It is not yet approved for patient use.
Is AMG 133 safe for humans based on this research?
This research only tested AMG 133 in animals (mice and monkeys), not humans. While results are promising, animal studies don’t guarantee human safety or effectiveness. Safety data will come from ongoing phase III clinical trials. Full safety profile won’t be known until human trial results are published.
Could AMG 133 work better than current GLP-1 drugs for weight loss?
Animal studies suggest the dual mechanism (GIPR blocking plus GLP-1 activation) may be more effective than GLP-1 alone, but this hasn’t been proven in humans yet. Direct comparison studies between AMG 133 and current drugs will be needed to determine if it’s truly superior.
What does the antibody component of AMG 133 do?
The antibody component carries the GLP-1 peptide and blocks GIPR receptors. Antibodies are large proteins that stay in the bloodstream much longer than peptides alone, which is why AMG 133 may only need monthly injections instead of weekly ones. This extended duration improves convenience for patients.
Want to Apply This Research?
- Track weekly body weight (same day, same time each week) and record energy levels, hunger ratings (1-10 scale), and blood sugar readings if available. This creates a baseline for comparing to future medication effects.
- Use the app to log current eating patterns and hunger triggers before any potential medication use. This establishes a baseline and helps identify which eating behaviors might be driven by the hunger hormones the drug targets (GIPR and GLP-1 pathways). Set reminders for medication administration once available.
- Create a long-term tracking dashboard showing weekly weight trends, monthly metabolic marker improvements (if tested), and subjective measures like appetite control and energy levels. Compare these metrics before and after starting any new obesity medication to objectively measure effectiveness.
This article discusses research on an experimental drug (AMG 133) currently in clinical trials and not yet approved by the FDA. The findings are based on animal studies and have not been confirmed in humans. This information is for educational purposes only and should not be considered medical advice. Do not attempt to obtain or use AMG 133 outside of authorized clinical trials. If you have obesity or are considering weight-loss medication, consult with a qualified healthcare provider about FDA-approved treatment options appropriate for your individual health situation. Clinical trial results, safety profiles, and efficacy in humans remain to be determined.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.